# Mitochondrial ROS dyshomeostasis: a key driver of accelerated supraspinatus atrophy after rotator cuff injury

**Authors:** Erkai Pang, Yijin Zou, Kongye Lu, Jian Li, Xuxu Chen, Yu Zhu, Tao Wang, Linlin Shi, Hui Kang

PMC · DOI: 10.3389/fphys.2026.1783596 · Frontiers in Physiology · 2026-03-12

## TL;DR

This paper reviews how mitochondrial ROS imbalance causes supraspinatus muscle atrophy after rotator cuff injuries and explores potential treatments.

## Contribution

The paper provides a comprehensive review of mtROS-driven mechanisms in supraspinatus atrophy and evaluates emerging therapeutic strategies.

## Key findings

- Excessive mitochondrial ROS causes oxidative damage and activates atrophy pathways in supraspinatus muscle.
- Biomechanical unloading and ischemic stress make the supraspinatus especially vulnerable to ROS-induced degeneration.
- Mitochondria-targeted antioxidants show promise but face translational challenges.

## Abstract

Rotator cuff injuries are common musculoskeletal disorders and are frequently accompanied by progressive supraspinatus muscle atrophy, which severely compromises functional recovery and surgical outcomes. Accumulating evidence indicates that mitochondrial reactive oxygen species (mtROS) dyshomeostasis is a central pathological driver of post-injury muscle degeneration. This review synthesizes current knowledge on the anatomical and histopathological changes following rotator cuff tears and focuses on the mechanisms governing mitochondrial ROS production, clearance, and dysregulation in the supraspinatus muscle. We highlight how excessive mtROS contribute to oxidative damage, mitochondrial dysfunction, impaired energy metabolism, and activation of key atrophy-related signaling pathways, including FOXO, NF-κB, MAPK, the ubiquitin-proteasome system, and the autophagy-lysosome pathway. Particular emphasis is placed on the unique biomechanical unloading, ischemic stress, and metabolic vulnerability of the supraspinatus following rotator cuff injury, which predispose this muscle to ROS-driven degeneration. Finally, we critically evaluate emerging therapeutic strategies targeting mtROS, including mitochondria-targeted antioxidants and conventional redox-modulating interventions, and discuss their translational potential and current limitations.

## Linked entities

- **Proteins:** foxo (forkhead box, sub-group O), NFKB1 (nuclear factor kappa B subunit 1), MAPK (mitogen activated kinase-like protein)

## Full-text entities

- **Genes:** NFKB1 (nuclear factor kappa B subunit 1) [NCBI Gene 4790] {aka CVID12, EBP-1, KBF1, NF-kB, NF-kB1, NF-kappa-B1}
- **Diseases:** metabolism (MESH:D008659), musculoskeletal disorders (MESH:D009140), ischemic (MESH:D002545), muscle degeneration (MESH:D009410), Rotator cuff injuries (MESH:D000070636), atrophy (MESH:D001284), post-injury (MESH:D004834), mitochondrial dysfunction (MESH:D028361), supraspinatus muscle atrophy (MESH:D009133)
- **Chemicals:** ROS (MESH:D017382), mtROS (-)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC13017390/full.md

## Figures

9 figures with captions in the complete paper: https://tomesphere.com/paper/PMC13017390/full.md

## References

118 references — full list in the complete paper: https://tomesphere.com/paper/PMC13017390/full.md

---
Source: https://tomesphere.com/paper/PMC13017390